Chemotherapy-Induced Thrombocytopenia Clinical Trial
Official title:
An Open-label, Multiple-Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia
The primary objective of this study is to evaluate the safety and tolerability of ONO-7746 across multiple doses in patients with solid tumors and chemotherapy induced thrombocytopenia (CIT) scheduled to receive at least two cycles of myelosuppressive chemotherapy on Day 1 every 21 days at the same dosages and schedule in the study. The secondary objectives are to characterize the PK profiles of ONO-7746 and to explore the pharmacodynamic effect of ONO-7746 on CIT.
n/a
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05969158 -
Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT03362177 -
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
|
Phase 3 | |
| Recruiting |
NCT05554913 -
Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia
|
Phase 2/Phase 3 | |
| Completed |
NCT05688306 -
To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment
|
||
| Completed |
NCT00283439 -
A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06099925 -
The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies
|
Phase 2 | |
| Completed |
NCT03471078 -
Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers
|
Phase 3 | |
| Active, not recruiting |
NCT03976882 -
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.
|
Phase 3 | |
| Recruiting |
NCT05772546 -
Avatrombopag vs. Placebo for CIT in GI Malignancies
|
Phase 2 | |
| Not yet recruiting |
NCT05864014 -
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.
|
Phase 3 | |
| Completed |
NCT01663441 -
A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11
|
Phase 3 | |
| Recruiting |
NCT05236582 -
Herombopag for Chemotherapy-induced Thrombocytopenia
|
Phase 2 | |
| Not yet recruiting |
NCT05944211 -
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia
|
Phase 2 | |
| Withdrawn |
NCT03343847 -
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.
|
Phase 3 | |
| Completed |
NCT05851027 -
Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT03049774 -
A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor
|
N/A | |
| Recruiting |
NCT03937154 -
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT05218226 -
Avatrombopag for Chemotherapy-induced Thrombocytopenia
|
Phase 2 | |
| Recruiting |
NCT04600960 -
Eltrombopag for Chemotherapy-induced Thrombocytopenia
|
Phase 2 | |
| Completed |
NCT00413283 -
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2 |